Please ensure Javascript is enabled for purposes of website accessibility

Why Zomedica Stock Popped Today

By Joe Tenebruso - May 17, 2021 at 2:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new executive will oversee the company's growth initiatives.

What happened

Shares of Zomedica (ZOM -0.43%) climbed on Monday after the veterinary health specialist announced a key hiring. As of 2:15 p.m. EDT, the stock's price was up more than 3% after rising as much as 9.3% earlier in the day.

So what 

Greg Blair will take on the role of vice president of business development. He will lead the company's acquisition and licensing efforts, as Zomedica seeks to expand its business.

Blair previously served in leadership positions at several healthcare companies, including Eli Lilly, Johnson & Johnson, and Intuitive Surgical. "Greg has the exact combination of industry knowledge, transactional experience, unlimited energy, and commitment to excellence needed to help bring Zomedica to the next level," CEO Robert Cohen said in a press release.

A person is pointing to an upwardly sloping line that's above a downwardly sloping line.

Investors bid up Zomedica's stock price on Monday. Image source: Getty Images.

Zomedica also said that Dr. Stephanie Morley, president and chief medical officer, will be stepping down. "As part of the original founding team who created the vision of Zomedica, Dr. Morley's accomplishments on behalf of the company are numerous and significant," Cohen said. "All of us at Zomedica are appreciative of her efforts and wish her the very best as she continues to expand her horizons."

Morley will continue to provide guidance to Zomedica's leadership team as a consultant.

Now what 

Zomedica announced the first sale of its promising Truforma veterinary diagnostics system for cats and dogs on March 16. Cohen said Zomedica will now use its hefty cash reserves to ramp up its Truforma-related commercialization initiatives, as well as to diversify its revenue sources.

"As disclosed in our first-quarter financials, Zomedica had a cash and cash equivalents balance of approximately $276.6 million as of March 31, 2021," Cohen said. "To complement our Truforma product platform and to accelerate the growth of Zomedica overall, we intend to opportunistically invest to expand our product offerings, technologies, and product development efforts."

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
ZOM
$0.37 (-0.43%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.